Opendata, web and dolomites

CAESAR SIGNED

Developing Therapeutic Antibodies for Pets

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAESAR project word cloud

Explore the words cloud of the CAESAR project. It provides you a very rough idea of what is the project "CAESAR" about.

chronic    team    antibodies    emotional    pets    untenable    phage    animals    severe    inflammation    inflammatory    suffering    generating    ibd    library    ineffective    therapies    managed    therapeutic    founded    5k    launch    sufficiently    companions    species    distress    put    causing    human    12    medical    medicine    first    15m    29bn    animal    poorly    40    demographic    relieve    revenue    german    gt    400    complete    caesar    expensive    people    solution    native    ge    causes    treat    display    licensing    diseases       cancer    canine    synthetic    overcome    immunogenic    veterinary    dogs    2million    expanding    royalties    2016    worth    pay    market    specializing    cagr    antibody    bowel    reliance    affordable    generate    adivo    3k    spend    2018    financial    biotech    health    demonstrated    owners    therapy    hire    company    shifts    synthesize    ease    companion    therapeutics    ownership    scalable    global    pet   

Project "CAESAR" data sheet

The following table provides information about the project.

Coordinator
ADIVO GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: PLANEGG
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADIVO GMBH DE (PLANEGG) coordinator 50˙000.00

Map

 Project objective

Chronic inflammatory diseases in pets such as Inflammatory Bowel Diseases (IBD) are poorly managed causing emotional and financial distress to pet owners. Current therapies are ineffective - they do not relieve pet suffering and lead to the animal being put down. Therapies are also expensive with costs up to €400/month. Antibody therapy for such conditions has long been used in human medicine but has not been sufficiently developed for veterinary medicine and causes an immunogenic response as the antibodies are not species specific. Antibodies need to be adapted which is expensive and causes severe side effects making them an untenable solution at present. Pet ownership in the EU has been on the increase (up by 2million pets since 2016) due to demographic shifts and a greater reliance on pets as companions. The global animal health market is worth > €29Bn growing at a CAGR of 6% with pet health making up 40% of the market. Pet owners spend €3k - €5k/ year on their pet’s health and are willing to pay to ease pet suffering. adivo is a German biotech company specializing in generating species-specific therapeutic antibodies for companion animals. adivo was founded in 2018. The adivo-team aims to address medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in future. adivo has developed CAESAR, the first of a kind synthetic canine phage-display library to generate therapeutic antibodies for dogs. We have developed a complete library from which we can synthesize therapeutic antibodies native to treat IBD. Our solution will overcome the challenges of current therapies and provide an affordable, scalable solution for effective antibody therapy for pets which has been demonstrated in human medicine. We expect to generate out-licensing revenue ≥€15M when we launch the product before royalties and hire 12 people.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAESAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAESAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

EASY-Diabetes (2019)

Individualised and Equitable Care of Type 2 Diabetes

Read More